Why the study?
Rapid pathogen screening is crucial against viral infections, especially during an overwhelming pandemic.
A novel CRISPR-empowered electrochemical biosensor provides a highly sensitive and selective platform for rapid, on-site detection of the H7N9 virus.
May advance research detection of H7N9; leaves open clinical translation pending human validation.
Rapid pathogen screening holds the key against certain viral infections, especially in an overwhelming pandemic. Herein, a CRISPR-empowered electrochemical biosensor was designed for the ultrasensitive detection of the avian influenza A (H7N9) virus gene sequence. Combining the CRISPR/Cas system, a signal-amplification strategy and a high-conductivity sensing substrate, the developed biosensor showed an ultrawide dynamic range, an ultralow detection limit, and excellent selectivity for H7N9 detection, providing a potential sensing platform for the simple, fast, sensitive, and on-site detection of infectious diseases.
No takes yet. Share an insight, caveat, or question.
Wan et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: